International Platform of Registered Systematic Review and Meta-analysis Protocols

INPLASY

Efficacy and treatment-related toxicities of antibody-drug conjugates in breast cancer

INPLASY2024110021
doi: 10.37766/inplasy2024.11.0021
Received: 4 November 2024
Published: 4 November 2024

Corresponding author:
Yiqun Han

han.yiqun@hotmail.com

Author Affiliation:
Mayo Clinic.

Han, Y; Welliver, M; Mutter, R.

ADMINISTRATIVE INFORMATION

Support - None.

Review Stage at time of this submission - Preliminary searches.

Conflicts of interest - None declared.

INPLASY registration number: INPLASY2024110021

Amendments - This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 4 November 2024 and was last updated on 4 November 2024.

INTRODUCTION

Review question / Objective To compare the efficacy and treatment-related adverse events of antibody-drug conjugates in breast cancer.

Condition being studied Patients with breast cancer treated with antibody-drug conjugates in RCTs.

METHODS

Participant or population Breast cancer patients, no matter molecular subtypes, disease stage, etc.

Intervention Antibody-drug conjugates.

Comparator Chemotherapy or physicians' choice.

Study designs to be included RCTs.

Eligibility criteria Breast cancer diagnosed with histology.

Information sources PubMed, Medline, Embase, Cochrane Library, ClinicalTrials.gov.

Main outcome(s) Progression-free survival, overall survival, TRAEs incidence
RR and 95%CI
HR and 95%CrI.

Quality assessment / Risk of bias analysis assessed based on selection, performance, detection, reporting bias, etc.

Strategy of data synthesis Using R gemtc package for the network meta-analysis for survival data and TRAEs, metafor package for direct comparisons.

Subgroup analysis molecular subtypes, disease stage, CD4/6 inhibitor treatment, etc.

Sensitivity analysis Remove the study successively to check the pooled data.

Language restriction English.

Country(ies) involved United States.

Keywords breast cancer, antibody-drug conjugates.

Contributions of each author

Author 1 - Yiqun Han.
Email: han.yiqun@hotmail.com
Author 2 - Meng Welliver.
Email: welliver.meng@mayo.edu
Author 3 - Robert Mutter.
Email: mutter.robert@mayo.edu